A prospective trial among breast cancer patients enrolled in The Pathways Study has found that higher levels of vitamin D can lower the risk of breast cancer morbidity and mortality.
Vitamin D can improve prognosis and overall survival (OS) in women being treated for breast cancer. These results, gathered from a study being led by researchers at the Roswell Park Cancer Institute and Kaiser Permanente, were published in JAMA Oncology.
Nutritional deficits are known to impact susceptibility to various diseases, including cancer, and vitamin D in particular has been the subject of several studies evaluating its association with cancer progression. While previous studies have shown an increased risk of breast cancer recurrence at distant sites and death in patients with vitamin D deficiency, the results remain controversial with some other studies negating the association.
Participants in the current trial were a part of The Pathways Study, established in 2006 within the integrated care delivery system of Kaiser Permanente Northern California. The trial documented a nearly 50% enrollment rate—enrollment halted in 2013, but follow-up continues, with milestones set at 12, 24, 48, 72, and 96 months after baseline interview. The trial, which used 25-hydroxyvitamin D (25OHD) as a surrogate readout for levels of vitamin D in the serum, used a case-cohort design for efficiency assay of 25OHD. Primary trial outcomes include breast cancer recurrence, second primary cancer, and death.
Data analysis showed that women with more advanced cancer had lower concentrations of serum 25OHD, with the lowest levels observed in premenopausal women with triple negative breast cancer. Further, levels of 25OHD inversely correlated with hazards of disease progression and death, the authors wrote—women with the highest tertile of 25OHD expression surviving the longest, following adjustment for clinical prognostic factors (hazard ratio [HR], 0.72; 95% CI, 0.54-0.98). Premenopausal women displayed the strongest association with OS (HR, 0.45; 95% CI, 0.21-0.96).
Based on their findings, the authors concluded that serum 25OHD levels are associated with patient prognosis in breast cancer, particularly among premenopausal women, and that higher levels of vitamin D can lower the risk breast cancer morbidity and mortality.
“This large prospective observational study provides compelling evidence that higher levels of vitamin D at the time of breast cancer diagnosis can reduce the risk of breast cancer progression and death,” Song Yao, PhD, associate professor of oncology in the Department of Cancer Prevention and Control at Roswell Park and first author on the study, said in a statement.
Reference
Yao S, Kwan ML, Ergas IJ, et al. Association of serum level of vitamin D at diagnosis with breast cancer survival: a case-cohort analysis in the pathways study [published online November 10, 2016]. JAMA Oncol. doi: 10.1001/jamaoncol.2016.4188.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More